Oxytocin CSE administration prior to | 47 (35%) | 37 (29%) | 52 (33%) | 56 (43%) | 0.18 |
VAPS difference before-CSE | 5.3 | 5.6 | 5.3 | 6.7 | |
minus after-CSE | (4.4–6.1) | (4.9–6.4) | (4.5–6.1) | (6.0–7.4) | 0.07 |
| n=60 | n=67 | n=69 | n=68 | |
Use of nalbuphine | 1 (0.7%) | 4 (3.1%) | 5 (3.1%) | 7 (5.3%) | 0.99 |
Use of diphenhydramine | 1 (0.7%) | 0 | 1 (0.6%) | 0 | 0.99 |
Decrease in MAP‡ > 20% after CSE | 50 (37%) | 50 (39%) | 62 (39%) | 45 (34%) | 0.24 |
Use of phenylephrine | 3 (2.2%) | 1 (0.8%) | 4 (2.5%) | 3 (2.3%) | 0.83 |
Use of ephedrine | 2 (1.5%) | 2 (1.6%) | 8 (5.0%) | 1 (0.8%) | 0.12 |
NRFHRC§ | 6 (4.4%) | 3 (2.3%) | 12 (7.6%) | 4 (3.0%) | 0.11 |
Use of nitroglycerine | 1 (0.7%) | 0 | 2 (1.3%) | 0 | 0.49 |
Use of terbutaline | 0 | 0 | 1 (0.6%) | 0 | 0.61 |
Emergent minutes after cesarean CSE delivery 30 | 0 | 0 | 2 (1.3%) | 0 | 0.25 |